Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
AT Taher, KM Musallam, M Karimi… - Blood, The Journal …, 2010 - ashpublications.org
Despite recent advances in understanding the pathophysiologic mechanisms behind the
thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide …
thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide …
Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran
M Karimi, H Darzi, M Yavarian - Journal of Pediatric Hematology …, 2005 - journals.lww.com
Hydroxyurea (HU) is a well-known chemotherapeutic agent that has been used largely for
the treatment of various myeloproliferative conditions over the past 20 years. In β-thalassemia, …
the treatment of various myeloproliferative conditions over the past 20 years. In β-thalassemia, …
[HTML][HTML] ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission
…, F Fabris, S Zver, M Réti, D Mikovic, M Karimi… - …, 2008 - haematologica.org
Background From 20 to 50% of patients who survive an acute episode of the acquired form
of thrombotic thrombocytopenic purpura relapse but clinical and laboratory markers of …
of thrombotic thrombocytopenic purpura relapse but clinical and laboratory markers of …
[HTML][HTML] Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and …
…, C Kattamis, M Angastiniotis, M Karimi… - Indian journal of …, 2013 - journals.lww.com
The current management of thalassemia includes regular transfusion programs and chelation
therapy. It is important that physicians be aware that endocrine abnormalities frequently …
therapy. It is important that physicians be aware that endocrine abnormalities frequently …
Spectrum of the Mutations in B ernard–S oulier Syndrome
…, B HadjKacem, PG Heller, M Karimi… - Human …, 2014 - Wiley Online Library
Bernard–Soulier syndrome ( BSS ) is a rare autosomal recessive bleeding disorder
characterized by defects of the GPIb‐IX‐V complex, a platelet receptor for von Willebrand factor ( …
characterized by defects of the GPIb‐IX‐V complex, a platelet receptor for von Willebrand factor ( …
[HTML][HTML] A randomized trial of factor VIII and neutralizing antibodies in hemophilia A
…, S Hanagavadi, R Varadarajan, M Karimi… - … England Journal of …, 2016 - Mass Medical Soc
Background The development of neutralizing anti–factor VIII alloantibodies (inhibitors) in
patients with severe hemophilia A may depend on the concentrate used for replacement …
patients with severe hemophilia A may depend on the concentrate used for replacement …
[HTML][HTML] β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint
…, AT Soliman, H Elsedfy, M Karimi… - … journal of hematology …, 2017 - ncbi.nlm.nih.gov
Background Haemoglobinopathies constitute the commonest recessive monogenic disorders
worldwide, and the treatment of affected individuals presents a substantial global disease …
worldwide, and the treatment of affected individuals presents a substantial global disease …
Factor XIII deficiency
M Karimi, Z Bereczky, N Cohan… - Seminars in thrombosis …, 2009 - thieme-connect.com
Factor XIII (FXIII) is a tetrameric zymogen (FXIII-A 2 B 2) that is converted into an active
transglutaminase (FXIIIa) by thrombin and Ca 2+ in the terminal phase of the clotting cascade. By …
transglutaminase (FXIIIa) by thrombin and Ca 2+ in the terminal phase of the clotting cascade. By …
[HTML][HTML] Adverse effects of prolonged sitting behavior on the general health of office workers
…, A Choobineh, H Ghaem, M Karimi - Journal of lifestyle …, 2017 - ncbi.nlm.nih.gov
Background Excessive sitting behavior is a risk factor for many adverse health outcomes.
This study aimed to survey the prevalence of sitting behavior and its adverse effects among …
This study aimed to survey the prevalence of sitting behavior and its adverse effects among …
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients
M Yavarian, M Karimi, E Bakker, CL Harteveld… - …, 2004 - haematologica.org
BACKGROUND AND OBJECTIVES: Hydroxyurea (HU) is known to increase gamma-globin
chain expression in postnatal life. The efficacy of HU treatment in thalassemia patients is still …
chain expression in postnatal life. The efficacy of HU treatment in thalassemia patients is still …